nach oben

AIDS and Behavior

Erschienen in:

01.10.2011 | Original Paper

Determinants of Optimal Adherence Over Time to Antiretroviral Therapy Amongst HIV Positive Adults in South Africa: A Longitudinal Study

verfasst von: Dikokole Maqutu, Temesgen Zewotir, Delia North, Kogieleum Naidoo, Anneke Grobler

Erschienen in: AIDS and Behavior | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Highly active antiretroviral therapy (HAART) requires strict adherence to achieve optimal clinical and survival benefits. A study was done to explore the factors affecting HAART adherence among HIV positive adults by reviewing routinely collected patient information in the Centre for the AIDS Programme of Research in South Africa’s (CAPRISA) AIDS Treatment Programme. Records of 688 patients enrolled between 2004 and 2006 were analysed. Patients were considered adherent if they had taken at least 95% of their prescribed drugs. Generalized estimating equations were used to analyse the data. The results showed that HAART adherence increased over time, however, the rate of increase differed by some of the socio-demographic and behavioural characteristics of the patients. For instance, HAART adherence increased in both urban and rural treatment sites over time, but the rate of increase was higher in the rural site. This helped identify sub-populations, such as the urban population, that required ongoing adherence counseling.

Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450–4.PubMedCrossRef

Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22–9.PubMedCrossRef

Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20(10):1053–6.PubMedCrossRef

Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.PubMed

Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.PubMedCrossRef

Knobel H, Guelar A, Valldecillo G, et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS. 2001;15(12):1591–3.PubMedCrossRef

Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 2):S171–6.PubMedCrossRef

Ferguson TF, Stewart KE, Funkhouser E, Tolson J, Westfall AO, Saag MS. Patient-perceived barriers to antiretroviral adherence: associations with race. AIDS Care. 2002;14(5):607–17.PubMedCrossRef

Murphy DA, Marelich WD, Hoffman D, Steers WN. Predictors of antiretroviral adherence. AIDS Care. 2004;16(4):471–84.PubMedCrossRef

10.

Penedo FJ, Gonzalez JS, Dahn JR, et al. Personality, quality of life and HAART adherence among men and women living with HIV/AIDS. J Psychosom Res. 2003;54(3):271–8.PubMedCrossRef

11.

Roca B, Lapuebla C, Vidal-Tegedor B. HAART with didanosine once versus twice daily: adherence and efficacy. Int J Infect Dis. 2005;9(4):195–200.PubMedCrossRef

12.

Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS. 2003;17(Suppl 3):S103–8.PubMedCrossRef

13.

Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26(1):82–92.PubMedCrossRef

14.

Mohammed H, Kieltyka L, Richardson-Alston G, et al. Adherence to HAART among HIV-infected persons in rural Louisiana. AIDS Patient Care STDS. 2004;18(5):289–96.PubMedCrossRef

15.

Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.PubMed

16.

Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265.PubMedCrossRef

17.

Bangsberg D, Emenyonu N, Andia I, et al. No decline in high levels of electronic pill cap, unannounced home pill count, and patient-reported adherence to free ARV therapy over 12 months in rural Uganda. In: 15th conference on retroviruses and opportunistic infections. Boston, Massachusetts, 3–6 Feb 2008 [abstract no. 801]. http://www.retroconference.org/2008/index.asp. Accessed 4 Feb 2010.

18.

Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS. 2005;16(1):38–41.PubMedCrossRef

19.

Muyingo SK, Walker AS, Reid A, et al. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr. 2008;48(4):468–75.PubMedCrossRef

20.

Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17(9):1369–75.PubMedCrossRef

21.

Etard JF, Laniece I, Fall MB, et al. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. Trop Med Int Health. 2007;12(10):1191–8.PubMedCrossRef

22.

Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government’s highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16(10):1363–70.PubMedCrossRef

23.

Iliyasu Z, Kabir M, Abubakar IS, Babashani M, Zubair ZA. Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano, Nigeria. Niger J Med. 2005;14(3):290–4.PubMed

24.

Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34(3):281–8.PubMedCrossRef

25.

Maqutu D, Zewotir T, North D, Naidoo K, Grobler A. Factors affecting early adherence to antiretroviral therapy amongst the HIV positive adults in South Africa. In: 50th annual conference of the South African statistical association, 29 Oct–2 Nov 2007. Johannesburg, South Africa.

26.

South African National Department of Health. National antiretroviral treatment guidelines. 1st ed. (2004). http://www.hst.org.za/uploads/files/sa_ART_gudelines1.pdf/. Accessed 7 May 2009.

27.

Littell RC, Milliken GA, Stroup WW, Wolfinger DR, Schabenberger O. SAS system for mixed models. 2nd ed. Cary, NC: SAS Institute Inc; 1999.

28.

Milliken GA, Johnson E. Analysis of messy data. New York: Chapman & Hall/CRC; 2002.

29.

Agresti A. Categorical data analysis. 2nd ed. New York: Wiley; 2002.CrossRef

30.

Liang K-Y, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22.CrossRef

31.

Pan W. Akaike’s information criterion in generalized estimating equations. Biometrics. 2001;57:120–5.PubMedCrossRef

32.

Hedeker D, Gibbons R. Longitudinal data analysis. New York: Wiley; 2006.

33.

Rubin DB. Inference and missing data. Biometrika. 1976;63:581–92.CrossRef

34.

Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. New York: Wiley; 2002.

35.

Fong OW, Ho CF, Fung LY, et al. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med. 2003;4(2):133–8.PubMedCrossRef

36.

Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response California Collaborative Treatment Group. AIDS. 1999;13(9):1099–107.PubMedCrossRef

37.

Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19(11):1111–7.PubMedCrossRef

38.

Skhosana N, Struthers H, Gray G, McIntyre J. HIV disclosure and other factors that impact on adherence to antiretroviral therapy: the case of Soweto, South Africa. AJAR. 2006;5(1):17–26.

39.

Harvey KM, Carrington D, Duncan J, et al. Evaluation of adherence to highly active antiretroviral therapy in adults in Jamaica. West Indian Med J. 2008;57(3):293–7.PubMed

40.

Birbeck GL, Chomba E, Kvalsund M, et al. Antiretroviral adherence in rural Zambia: the first year of treatment availability. Am J Trop Med Hyg. 2009;80(4):669–74.PubMed

41.

Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clin Care. 1997;9(7):51–4, 8.PubMed

42.

Godin G, Cote J, Naccache H, Lambert LD, Trottier S. Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. AIDS Care. 2005;17(4):493–504.PubMedCrossRef

43.

Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29(Suppl 1):S2–10.PubMed

44.

Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care. 2002;14(3):309–18.PubMedCrossRef

45.

Abel E, Painter L. Factors that influence adherence to HIV medications: perceptions of women and health care providers. J Assoc Nurses AIDS Care. 2003;14(4):61–9.PubMedCrossRef

46.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146(8):564–73.PubMed

47.

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.PubMedCrossRef

48.

Chang LW, Kagaayi J, Nakigozi G, et al. Telecommunications and health Care: an HIV/AIDS warmline for communication and consultation in Rakai, Uganda. J Int Assoc Physicians AIDS Care (Chic Ill). 2008;7(3):130–2.CrossRef

49.

Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.PubMedCrossRef

Titel: Determinants of Optimal Adherence Over Time to Antiretroviral Therapy Amongst HIV Positive Adults in South Africa: A Longitudinal Study
verfasst von: Dikokole Maqutu
Temesgen Zewotir
Delia North
Kogieleum Naidoo
Anneke Grobler
Publikationsdatum: 01.10.2011
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 7/2011
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-010-9688-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Determinants of Optimal Adherence Over Time to Antiretroviral Therapy Amongst HIV Positive Adults in South Africa: A Longitudinal Study

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2011

Work-related Barriers and Facilitators to Antiretroviral Therapy Adherence in Persons Living with HIV Infection

The Skinny on Sexual Risk: The Effects of BMI on STI Incidence and Risk

Risk Factors for Medication Non-Adherence in an HIV Infected Population in the Dominican Republic

Adherence to Highly Active Antiretroviral Therapy (HAART): A Meta-Analysis

Food Insufficiency is a Risk Factor for Suboptimal Antiretroviral Therapy Adherence among HIV-Infected Adults in Urban Peru

Longitudinal Determinants of Consistent Condom Use by Partner Type Among Young Injection Drug Users: The Role of Personal and Partner Characteristics

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin